ARCA Recruiting Studies
- VEST QD: A 48-week Protease Inhibitor switch study substituting Sustiva for the present PI in patients with viral load<50 Copies/mL on their first PI-based Anti-Retroviral Regimen.
- SMART: A Large Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study).
- 1002: This is a 48-week study with an extension in place for patients who respond favorably to an investigational NNRTI, Capravirine.
- 1006: This study is looking at three doses of Capravirine (NNRTI) 700mg BID, 400mg BID and 200mg BID vs Placebo and two different doses of Kaletra, plus 2 NRTI’s.
- 1010: This is a 48-week, treatment naive study (cannot have taken HIV medications in the past) studying an “OPEN LABEL” new dose of Viracept (“2” 625mg BID) to lessen pill burden in combination with Combivir.
- CAL 30001: A study for HIV-positive people who are currently taking a triple combination therapy, and are experiencing an increasing viral load.
- ESS 30008: A study for HIV-positive people who are currently taking Abacavir and Lamivudine (3TC) plus a NNRTI or a PI
- M00-261: The purpose of the M00-261 study is to look at possible anti-HIV regimens that might work after Kaletra stops working (or is failing) because the HIV in your body has become resistant.
- M01-287: The purpose of the M01-287 study is to look at possible anti-HIV regimens that might work after Kaletra stops working (or is failing) because the HIV in your body has become resistant.
- Merck 013: The purpose of the Merck 013 study is to study people who start anti-HIV medications very soon after being infected with HIV.